NEW YORK, Sept. 10 – Amersham Pharmacia Biotech has licensed green fluorescent protein technology from Aurora Biosciences, the company announced Monday.
The license gives APBiotech worldwide exclusive rights to the technology, said Kevin McCormack, marketing director for lead screening systems at APBiotech.
The company would not disclose the length of the licensing agreement or financial details of the agreement.
GFP technology aids researchers in identifying cellular expressions of a gene by enabling fluorescent detection of the phenotype. Applications of the technology include functional genomics, high-throughput screening assays, and gene profiling to assess the potential toxicity of compounds.
McCormack said the Aurora license would augment the GFP technology APBiotech already licenses from Denmark-based BioImage, giving customers one-stop access to GFP technology.
“In order to utilize GFP, you need a specific set of mutations, a very complex web of IP,” said McCormack. “Pooling IP from Aurora and BioImage gives a complete portfolio of IP for our customers.”